Aspen's earnings call highlighted significant achievements, particularly in revenue and EBITDA growth, successful acquisitions, and promising opportunities in the GLP-1 market. However, challenges such as currency impacts, difficulties in China, and increased tax and working capital levels posed notable concerns.

Company Guidance -

Q4 2025

During the call, Aspen provided guidance for fiscal year 2025 with several key metrics. The company reported a 9% increase in revenue in constant currency and a 21% growth in normalized EBITDA at constant exchange rates, significantly surpassing revenue growth. The Commercial Pharma segment achieved double-digit growth in both revenue and EBITDA, while the Manufacturing segment saw a 65% increase in finished dose form (FDF) growth. Aspen also projected double-digit compound annual growth in EBITDA and forecasted operating cash flow conversion rates to exceed 100%. Additionally, the company highlighted its focus on the GLP-1 opportunity, anticipating first revenues in financial year 2026, with a strong contribution to future growth. The Finance cost effective interest rate was noted at approximately 5%, and the tax rate increased to 21.6%. Aspen's operating cash flow was expected to improve, targeting a working capital to revenue ratio of 45% by year-end.

Strong Revenue Growth

Aspen reported a 9% revenue growth at constant exchange rates (CER) and 4% in reported terms, highlighting a robust performance despite currency fluctuations.

Normalized EBITDA Surge

Normalized EBITDA increased by 21% at CER and 12% in reported terms, significantly outpacing revenue growth and demonstrating strong operational efficiency.

Commercial Pharma Performance

The Commercial Pharma segment achieved double-digit growth with revenue and EBITDA both increasing. The segment is derisked from major market headwinds, such as China VBP and Russia.

Successful LatAm Acquisition

The acquisition in Latin America was executed seamlessly, achieving over 100% of expected sales, marking a significant milestone for Aspen in the region.

GLP-1 Opportunity

Aspen is well-positioned in the GLP-1 market, with submissions underway and positive feedback from stringent regulators, marking a transformative opportunity for the company.

Sustainability Initiatives

Aspen outlined ambitious sustainability goals, including reducing carbon emissions by 50% by 2030 and achieving gender balance in top management.

Aspen Pharmacare (APNHY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

APNHY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Sep 03, 2025	2025 (Q4)	- / -	0.251	―	―	―
Mar 03, 2025	2025 (Q2)	- / 0.35	0.326	6.44% (+0.02)
Oct 02, 2024	2024 (Q4)	0.57 / 0.25	0.393	-36.13% (-0.14)
Mar 04, 2024	2024 (Q2)	- / 0.33	0.369	-11.65% (-0.04)
Aug 30, 2023	2023 (Q4)	0.48 / 0.39	0.45	-12.67% (-0.06)
Mar 01, 2023	2023 (Q2)	- / 0.37	0.528	-30.11% (-0.16)
Aug 31, 2022	2022 (Q4)	0.48 / 0.45	0.326	38.04% (+0.12)	―	―
Mar 09, 2022	2022 (Q2)	- / 0.53	0.403	31.02% (+0.13)	―	―
Sep 01, 2021	2021 (Q4)	0.38 / 0.33	0.288	13.19% (+0.04)	―	―
Mar 11, 2021	2021 (Q2)	- / 0.40	0.439	-8.20% (-0.04)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

APNHY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 03, 2025	$8.79	$9.82	+11.72%
Oct 02, 2024	$11.23	$11.26	+0.27%
Mar 04, 2024	$10.18	$10.60	+4.13%
Aug 30, 2023	$9.81	$9.01	-8.15%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aspen Pharmacare (APNHY) report earnings?

Aspen Pharmacare (APNHY) is schdueled to report earning on Sep 03, 2025, TBA (Confirmed).

What is Aspen Pharmacare (APNHY) earnings time?

Aspen Pharmacare (APNHY) earnings time is at Sep 03, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is APNHY EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing